Zachou Maria, Pikramenos Konstantinos, Panoutsakou Maria, Lalla Efthimia, Androutsakos Theodoros
Second Department of Propaedeutic Surgery, "Laikon" General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, GRC.
Gastroenterology, Sismanogleio General Hospital of Athens, Athens, GRC.
Cureus. 2022 Dec 14;14(12):e32525. doi: 10.7759/cureus.32525. eCollection 2022 Dec.
Infliximab (IFX) is a chimeric human-murine monoclonal antibody that prevents tumor necrosis factor alpha (TNF-α) activation by binding to both soluble and transmembrane forms of TNF-α. Antagonists of TNF (anti-TNF agents) can cause drug-induced liver injury (DILI). We present a non-anti-TNF naïve patient suffering from severe Crohn's disease who developed DILI with a hepatocellular pattern, without jaundice, after two infusions of an IFX biosimilar.
英夫利昔单抗（IFX）是一种嵌合型人鼠单克隆抗体，通过与可溶性和跨膜形式的肿瘤坏死因子α（TNF-α）结合来阻止其激活。TNF拮抗剂（抗TNF药物）可导致药物性肝损伤（DILI）。我们报告了一名未使用过抗TNF药物的重度克罗恩病患者，在输注两次IFX生物类似药后出现了肝细胞型DILI，但无黄疸。
